← 返回

NK 细胞在癌症和癌症免疫治疗中的作用

英文原题:Natural Killer Cells in Cancer and Cancer Immunotherapy.

查看英文原题

Natural Killer Cells in Cancer and Cancer Immunotherapy.

PubMed 2021/07/22(内容时间) Cancer Lett Q1 · IF 11.8(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

中文摘要

肿瘤细胞的检测和杀伤需要多种抗肿瘤效应细胞的协调作用。固有免疫系统中的自然杀伤(NK)细胞处于机体防御系统的前沿,证据表明,NK细胞在癌组织中的浸润和细胞毒性影响治疗效果和生存期。作为抗癌免疫反应中的强大效应细胞,NK细胞能迅速识别并杀伤转化细胞,而对健康自身组织反应性很低,这凸显了它们在癌症免疫治疗中的潜在作用。现代免疫治疗方法包括免疫检查点抑制剂以 revitalize 功能失调的T细胞,以及使用嵌合抗原受体的CD8+ T细胞进行过继细胞转移以增强其功能。然而,治疗反应可能短暂,且因不良反应而停药的风险要求开发更安全、疗效更好的免疫肿瘤疗法。为此,目前正在研究使用T细胞和NK细胞的新型联合干预措施以及克服相关挑战的策略。本综述总结了NK细胞在癌症和癌症免疫治疗中的研究进展,并讨论了未来癌症治疗的可能意义。

展开英文摘要原文

The detection and killing of neoplastic cells require coordination of a variety of antitumor effector cells. Natural killer (NK) cells of the innate immune system are at the forefront of the body's defense systems and evidence suggests that the infiltration and cytotoxicity of NK cells in the cancer tissue influence treatment efficacy and survival.

As powerful effectors in the anticancer immune response, NK cells rapidly recognize and kill transformed cells with little reactivity against healthy self-tissues, which highlights their potential role in cancer immunotherapy. Modern immunotherapeutic approaches include immune checkpoint inhibitors to revitalize dysfunctional T cells and adoptive cell transfer using CD8 + T cells with chimeric antigen receptors to enhance their functionality.

However, treatment responses may be short-lived and risk of discontinuation due to adverse effects necessitates the development of safer immuno-oncologic therapies with improved outcomes. To this end, novel combinatorial interventions using T cells and NK cells and strategies for overcoming associated challenges are currently being investigated. This review summarizes the advances in the research on NK cells in cancer and cancer immunotherapy and discusses the possible implications for future cancer treatment.

论文信息

作者
Raskov H、Orhan A、Salanti A、Gaggar S、Gögenur I
第一作者单位
Center for Surgical Science, Zealand University Hospital, Lykkebækvej 1, DK-4600, Køge, Denmark. Electronic address: hansr@regionsjaelland.dk.Denmark
通讯作者单位
Center for Surgical Science, Zealand University Hospital, Lykkebækvej 1, DK-4600, Køge, Denmark; Department of Clinical Medicine, University of Copenhagen, Blegdamsvej 3B, DK-2200, Copenhagen, Denmark. Electronic address: igo@regionsjaelland.dk.Denmark
文献类型
综述
期刊
Cancer letters2021 Nov 1
原文标识
PubMed 34302920 · DOI 10.1016/j.canlet.2021.07.032